Neurology Medical News about Cyclophosphamide Multiple Sclerosis

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Doctors and the DEA Free full text

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Review: Cyclophosphamide in multiple sclerosis: scientific rationale, history and novel treatment paradigms
Therapeutic Advances in Neurological Disorders, 11/10/09

Awad A et al. – Cyclophosphamide (CYC), an alkylating agent, penetrates the blood–brain barrier and CNS parenchyma well. However, while CYC has been used in clinical trials and off–label in clinical practice in patients with MS for over three decades, data on its efficacy in very heterogeneous groups of study patients have been conflicting. New myeloablative treatment paradigms with CYC may provide a therapeutic option in patients that do not respond to other agents. In this article the authors review the scientific rationale that led to the initial clinical trials with CYC. The authors will also outline the safety, tolerability and efficacy of CYC and provide neurologists with guidelines for its use in patients with MS and other inflammatory disorders of the CNS, including neuromyelitis optica (NMO). Finally, an outlook into relatively novel treatment approaches is provided.

<< Previous
Anesthesia and intraoperative neurophysiological monitoring in...

Next >>
Cerebral venous sinus thrombosis: review of the demographics,...

Early Psychiatric Manifestation in a Patient with Primary Progressive Multiple Sclerosis
Archives of Iranian Medicine, 11/12/09 Relevance Score: 69%

Cochlear implantation in a profoundly deaf patient who also suffers from multiple sclerosis - a case study
Cochlear Implants International, 10/27/09 Relevance Score: 69%

A single-centre, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis
Multiple Sclerosis, 10/01/09 Relevance Score: 69%

Regulatory and pro-inflammatory phenotypes of myelin basic protein-autoreactive T cells in multiple sclerosis
International Immunology, 10/14/09 Relevance Score: 68%

Early Drug Treatment May Cut Multiple Sclerosis Risk
MedLinePlus, 10/08/09 Relevance Score: 68%